Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
FBRX vs CELU: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FBRX Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 8–0 Matrix Metrics)
FBRX Overall Winner
6-Pillar Tally: FBRX 3 – 2 CELU (1 Tie)
Matrix Metrics: FBRX 8 – 0 CELU
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin).
- Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FBRX vs CELU
FBRX
Head-to-Head Winner
Forte Biosciences, Inc. Common Stock
$76.99
+0.03% 1D
Market Cap
$1.6B
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.09β · 3% Vol
Unified Composite Score
52.7
HOLD
Tech 49.0
Fund 51.0
Flow 62.0
Mom 40.0
Weinstein Technical Phase
Markup · Hold / add on dips
CELU
Celularity Inc. Class A Common Stock
$0.46
-1.05% 1D
Market Cap
$15.2M
TTM Revenue
$19M
Forward P/E
N/M
Beta / 30D Vol
2.01β · 135% Vol
Unified Composite Score
42.9
HOLD
Tech 25.0
Fund 48.0
Flow 67.0
Mom 55.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (FBRX 3 – 2 CELU)
1. Valuation Multiples
CELU
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
N/M
2.7x
2. Growth & Scale
FBRX
Revenue Growth (YoY)
+0.0%
-5.3%
Earnings Growth (YoY)
+0.0%
-61.3%
TTM Revenue (USD)
N/A
$19M
Market Cap
$1.6B
$15.2M
3. Profitability & Quality
FBRX
Gross Margin
N/A
19.2%
Operating Margin
0.0%
-254.0%
Net Profit Margin
0.0%
-245.7%
Return on Equity (ROE)
-62.3%
-6367.2%
4. Balance Sheet & Cash Flow
CELU
Cash Generation (TTM)
-$72M
-$8.9M
Cash Flow Margin
N/A
-47.8%
Net Cash / Leverage
$7.52 Book/Sh · -62.3% ROE
$35M Net Debt
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FBRX
Options Structure Phase
UNCLASSIFIED
BREAKDOWN
Current IV / %ile
11.1% (3rd %ile)
116.6% (50th %ile)
Put/Call OI Skew
0.77x (Call-Skewed)
3.60x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FBRX (8) vs CELU (0)| Institutional Metric | FBRX | CELU | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $1.6B | $15.2M | FBRX | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +0.0% | -5.3% | FBRX | |
| Operating Margin (TTM) | 0.0% | -254.0% | FBRX | |
| Net Profit Margin | 0.0% | -245.7% | FBRX | |
| Return on Equity (ROE) | -62.3% | -6367.2% | FBRX | |
| 52-Week Range Position | 100% ($10–$77) | 2% ($0–$3) | FBRX | |
| Beta / 30D Volatility | 1.09β · 3% Vol | 2.01β · 135% Vol | FBRX | |
| Unified Institutional Score | 52.7 / 100 (HOLD) | 42.9 / 100 (HOLD) | FBRX | |
| Trailing 12M Revenue (USD) | N/A | $19M | Scale | |
| Gross Profit Margin (TTM) | N/A | 19.2% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 2.7x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$72M ($7.52 Book/Sh · -62.3% ROE) | -$8.9M ($35M Net Debt) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CELU +15.39 pp
3M Horizon
FBRX +262.38 pp
6M Horizon
FBRX +200.28 pp
1Y Horizon
FBRX +359.4 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FBRX Revenue | CELU Revenue | FBRX Op. Margin | CELU Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $20M | N/A | -254.2% | N/A | FBRX |
| FY2019 | $0M | N/A | -11288.9% | N/A | FBRX |
| FY2020 | N/A | $10M | N/A | -1064.0% | CELU |
| FY2021 | N/A | $20M | N/A | -511.2% | CELU |
| FY2022 | N/A | $20M | N/A | -142.4% | CELU |
| FY2023 | N/A | $20M | N/A | -844.4% | CELU |
| FY2024 | N/A | $50M | N/A | -70.7% | CELU |
| FY2025 | N/A | $30M | N/A | -230.9% | CELU |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FBRX
UNCLASSIFIED
Current IV
11.1%
IV Percentile
3rd %ile
Put/Call OI Skew
0.77x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FBRX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CELU
BREAKDOWN
Current IV
116.6%
IV Percentile
50th %ile
Put/Call OI Skew
3.60x (Put-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact CELU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FBRX Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CELU Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FBRX vs CELU Key Questions & Quantitative Answers
As of Nov 20, 2026, Forte Biosciences, Inc. (FBRX) is the stronger overall head-to-head candidate over Celularity Inc. (CELU) in the Tradestie Institutional Equity Comparison Engine, winning 8–0 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). FBRX carries a Unified Composite Score of 52.7/100 (HOLD) at $76.99 (N/M Forward P/E, 0.0% operating margin), whereas CELU carries 42.9/100 (HOLD) at $0.46 (N/M Forward P/E, -254.0% operating margin). Technical & Structure Timing Caution: FBRX trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 84.7); meanwhile CELU is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 26.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
FBRX leads the Growth & Scale pillar: FBRX posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CELU at -5.3% YoY revenue growth and -61.3% YoY earnings growth on $19M TTM revenue (19.2% gross margin, -254.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), FBRX cumulative revenue shifted N/A while CELU shifted +200.0%. In operating R&D and SG&A reinvestment, FBRX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CELU.
CELU screens cheaper on headline valuation multiples. FBRX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CELU trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 2.7x EV/Revenue (-47.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FBRX (-62.3% ROE) versus CELU (-6367.2% ROE) capital efficiency.
In options market volatility and institutional positioning, FBRX carries 11.1% implied volatility (3rd %ile, Compressed (<25th %ile)), a 0.77x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.09β · 3% Vol realized risk). By comparison, CELU carries 116.6% implied volatility (50th %ile, Balanced (25th–60th %ile)), a 3.60x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 135% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CELU vs FBRX · Reverse Pair
FBRX vs KRSA
· Sector Peer
FBRX vs DMRA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal